AHL Partners’s Celgene Corp CELG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
$2.14M Sell
20,534
-22,221
-52% -$2.51M 0.03% 698
2017
Q3
$6.24M Buy
42,755
+9,401
+28% +$1.28M 0.11% 323
2017
Q2
$4.33M Buy
33,354
+22,038
+195% +$2.7M 0.09% 401
2017
Q1
$1.41M Buy
11,316
+8,976
+384% +$1.07M 0.03% 705
2016
Q4
$271K Buy
+2,340
New +$261K 0.01% 981
2016
Q1
Sell
-13,099
Closed -$1.57M 885
2015
Q4
$1.57M Buy
13,099
+10,835
+479% +$1.25M 0.12% 309
2015
Q3
$245K Sell
2,264
-40,036
-95% -$4.97M 0.04% 620
2015
Q2
$4.9M Sell
42,300
-2,860
-6% -$327K 0.2% 186
2015
Q1
$5.21M Buy
45,160
+22,802
+102% +$2.72M 0.21% 165
2014
Q4
$2.5M Buy
+22,358
New +$2.36M 0.13% 348

Other funds holding CELG

AHL Partners's CELG Position: Q4 2017 in Review

AHL Partners reduced its Celgene Corp (CELG) stake by 52% in Q4 2017, selling an estimated $2.51M and leaving 20,534 shares worth $2.14M. The position accounts for 0.03% of the portfolio, ranked #698.

AHL Partners first reported a position in CELG in Q4 2014 and has held it in 10 quarters since. The position peaked at $6.24M in Q3 2017. 1,470 funds tracked by Wall St. Rank hold CELG as of Q4 2017.

  • AHL Partners held 20,534 shares of Celgene Corp worth $2.14M as of Q4 2017.
  • AHL Partners sold 22,221 Celgene Corp shares in Q4 2017, an estimated $2.51M.
  • Celgene Corp made up 0.03% of AHL Partners's portfolio in Q4 2017, its #698 holding.
  • AHL Partners first reported a position in Celgene Corp in Q4 2014 and has held it in 10 quarters since.
  • AHL Partners's Celgene Corp position peaked at $6.24M in Q3 2017.
  • 1,470 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.